Survival Outcomes Associated with Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pancreatic Cancer

Francis I. Macedo, Emily Ryon, Shishir K. Maithel, Rachel M. Lee, David A. Kooby, Ryan C. Fields, William G. Hawkins, Greg Williams, Ugwuji Maduekwe, Hong J. Kim, Syed A. Ahmad, Sameer H. Patel, Daniel E. Abbott, Patrick Schwartz, Sharon M. Weber, Charles R. Scoggins, Robert C.G. Martin, Vikas Dudeja, Dido Franceschi, Alan S. LivingstoneNipun B. Merchant

Research output: Contribution to journalArticlepeer-review

18 Scopus citations

Abstract

Objective:To compare the survival outcomes associated with clinical and pathological response in pancreatic ductal adenocarcinoma (PDAC) patients receiving neoadjuvant chemotherapy (NAC) with FOLFIRINOX (FLX) or gemcitabine/nab-paclitaxel (GNP) followed by curative-intent pancreatectomy.Background:Newer multiagent NAC regimens have resulted in improved clinical and pathological responses in PDAC; however, the effects of these responses on survival outcomes remain unknown.Methods:Clinicopathological and survival data of PDAC patients treated at 7 academic medical centers were analyzed. Primary outcomes were overall survival (OS), local recurrence-free survival (L-RFS), and metastasis-free survival (MFS) associated with biochemical (CA 19-9 decrease ≥50% vs <50%) and pathological response (complete, pCR; partial, pPR or limited, pLR) following NAC.Results:Of 274 included patients, 46.4% were borderline resectable, 25.5% locally advanced, and 83.2% had pancreatic head/neck tumors. Vein resection was performed in 34.7% and 30-day mortality was 2.2%. R0 and pCR rates were 82.5% and 6%, respectively. Median, 3-year, and 5-year OS were 32 months, 46.3%, and 30.3%, respectively. OS, L-RFS, and MFS were superior in patients with marked biochemical response (CA 19-9 decrease ≥50% vs <50%; OS: 42.3 vs 24.3 months, P < 0.001; L-RFS-27.3 vs 14.1 months, P = 0.042; MFS-29.3 vs 13 months, P = 0.047) and pathological response [pCR vs pPR vs pLR: OS-not reached (NR) vs 40.3 vs 26.1 months, P < 0.001; L-RFS-NR vs 24.5 vs 21.4 months, P = 0.044; MFS-NR vs 23.7 vs 20.2 months, P = 0.017]. There was no difference in L-RFS, MFS, or OS between patients who received FLX or GNP.Conclusion:This large, multicenter study shows that improved biochemical, pathological, and clinical responses associated with NAC FLX or GNP result in improved OS, L-RFS, and MFS in PDAC. NAC with FLX or GNP has similar survival outcomes.

Original languageEnglish (US)
Pages (from-to)400-413
Number of pages14
JournalAnnals of surgery
Volume270
Issue number3
DOIs
StatePublished - Sep 1 2019

Keywords

  • FOLFIRINOX
  • gemcitabine/nabpaclitaxel
  • neoadjuvant chemotherapy
  • outcomes
  • pancreatic cancer
  • survival

ASJC Scopus subject areas

  • Surgery

Fingerprint Dive into the research topics of 'Survival Outcomes Associated with Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pancreatic Cancer'. Together they form a unique fingerprint.

Cite this